Patents by Inventor Mike A. Clark

Mike A. Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR MODULATING PROLINE LEVELS
    Publication number: 20120003207
    Abstract: Methods and compositions for modulating amino acid levels in a subject are provided herein.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 5, 2012
    Applicant: ONCOPHARMACOLOGICS, INC.
    Inventor: Mike A. Clark
  • MODIFIED TUMOR NECROSIS FACTOR-BETA
    Publication number: 20100284962
    Abstract: Compositions including modified TNF-beta polypeptides and methods of using the compositions are disclosed herein.
    Type: Application
    Filed: May 6, 2009
    Publication date: November 11, 2010
    Applicant: OncoPharmacologics, Inc.
    Inventor: Mike A. Clark
  • Modified tumor necrosis factor
    Patent number: 7785579
    Abstract: Modifying TNF with polyethyleneglycol (PEG) having an approximate weight average molecular weight in the range of about 10,000 to about 40,000, preferably in the range of about 20,000 to 30,000, significantly increases the circulating half-life of the TNF while not increasing its toxicity. As a result, lower doses of the TNF may be administered to effectively treat tumors with fewer, accompanying adverse side effects to the patient.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: August 31, 2010
    Assignee: Polaris Group
    Inventor: Mike A. Clark
  • METHODS AND COMPOSITIONS FOR MODULATING PROLINE LEVELS
    Publication number: 20100150949
    Abstract: Methods and compositions for modulating amino acid levels in a subject are provided herein.
    Type: Application
    Filed: December 16, 2008
    Publication date: June 17, 2010
    Applicant: ONCOPHARMACOLOGICS, INC.
    Inventor: Mike A. Clark
  • Method of treatment with modified arginine deiminase
    Patent number: 7323167
    Abstract: The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods of treating cancer, and to methods of treating and/or inhibiting metastasis.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: January 29, 2008
    Assignee: Polaris Group
    Inventor: Mike A. Clark
  • PEG-modified uricase
    Patent number: 6913915
    Abstract: The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: July 5, 2005
    Assignee: Phoenix Pharmacologics, Inc.
    Inventors: Charles Mark Ensor, Mike A. Clark, Frederick Wayne Holtsberg
  • Novel mutated form of arginine deiminase
    Publication number: 20040258675
    Abstract: The present invention discloses arginine deiminase that is genetically modified for more efficient manufacturing and processing. The present invention discloses recombinant DNA molecules and vectors and other therapeutic and pharmaceutical compositions. The present invention also discloses methods for preparing modified arginine deiminase as well as methods of treating cancer and other disease states using modified arginine deiminase.
    Type: Application
    Filed: August 21, 2003
    Publication date: December 23, 2004
    Applicant: Phoenix Pharmacologics, Inc.
    Inventors: Charles Mark Ensor, Frederick Wayne Holtsberg, Mike A. Clark
  • Modified arginine deiminase
    Patent number: 6737259
    Abstract: The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods of treating cancer, and to methods of treating and/or inhibiting metastasis.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: May 18, 2004
    Assignee: Phoenix Pharmacologics, Inc.
    Inventor: Mike A. Clark
  • Yeast expression systems, methods of producing polypeptides in yeast, and compositions relating to same
    Patent number: 6645739
    Abstract: The present invention provides novel expression systems for producing desired polypeptides in certain strains of yeast. The present invention further provides methods for producing polypeptide products using such expression systems. The present invention also provides compositions relating to the same.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: November 11, 2003
    Assignee: Phoenix Pharmacologies, Inc.
    Inventor: Mike A. Clark
  • Mutated form of arginine deiminase
    Patent number: 6635462
    Abstract: The present invention discloses arginine deiminase that is genetically modified for more efficient manufacturing and processing. The present invention discloses recombinant DNA molecules and vectors and other therapeutic and pharmaceutical compositions. The present invention also discloses methods for preparing modified arginine deiminase as well as methods of treating cancer and other disease states using modified arginine deiminase.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: October 21, 2003
    Assignee: Phoenix Pharmacologies, Inc.
    Inventors: Charles Mark Ensor, Frederick Wayne Holtsberg, Mike A. Clark
  • Yeast expression systems, methods of producing polypeptides in yeast, and compositions relating to same
    Publication number: 20030092099
    Abstract: The present invention provides novel expression systems for producing desired polypeptides in certain strains of yeast. The present invention further provides methods for producing polypeptide products using such expression systems. The present invention also provides compositions relating to the same.
    Type: Application
    Filed: July 26, 2001
    Publication date: May 15, 2003
    Inventor: Mike A. Clark
  • PEG-modified uricase
    Publication number: 20030082786
    Abstract: The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.
    Type: Application
    Filed: August 2, 2001
    Publication date: May 1, 2003
    Inventors: Charles Mark Ensor, Mike A. Clark, Frederick Wayne Holtsberg
  • Modified arginine deiminase
    Patent number: 6183738
    Abstract: The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods of treating cancer, and to methods of treating and/or inhibiting metastasis.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: February 6, 2001
    Assignee: Phoenix Pharamacologics, Inc.
    Inventor: Mike A. Clark
  • Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
    Patent number: 5786154
    Abstract: The invention provides methods for detecting elevated levels of phospholipase A.sub.2 activating protein in persons suspected of having rheumatoid arthritis to thereby indicate the presence of rheumatoid arthritis in the person comprising the steps of providing a sample of body fluid or tissue from said person; contacting the sample with an antibody specific for phospholipase A.sub.2 activating protein such that the antibody binds with phospholipase A.sub.2 activating protein in the sample; detecting the antibody thereby indicating the presence of phospholipase A.sub.2 activating protein, whereby elevated levels of phospholipase A.sub.2 activating protein in the sample as compared with levels found in persons not having rheumatoid arthritis indicates the presence of rheumatoid arthritis in the person. Kits and reagents for detecting rheumatoid arthritis are also provided.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 28, 1998
    Inventors: John S. Bomalaski, Mike A. Clark, Robert Shorr
  • Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
    Patent number: 5728560
    Abstract: The present invention is directed to methods of treating CD4+ T cell lymphopenia in HIV-infected patients. The methods include administering an effective mount of adenosine deaminase or related enzymatic material to a patient in need thereof. In preferred aspects of the invention, the method is employed in conjunction with HIV-infected patients having CD4+ T cell levels of less than about 200/.mu.l. Effective amounts of the enzyme range from about 5 to about 50 IU/kg/week. In one particularly preferred aspect of the invention, the adenosine deaminase is conjugated to one or more strands of polyethylene glycol to prolonged activity in vivo.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: March 17, 1998
    Assignee: Enzon, Inc.
    Inventors: Robert G. L. Shorr, Mike A. Clark, David H. Goddard
  • Reduction of mammalian neoplasms with phospholipase A2 activating substances
    Patent number: 5527775
    Abstract: Methods of treating mammalian neoplastic disease are disclosed using phospholipase A.sub.2 activating proteins and fragments thereof.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: June 18, 1996
    Assignee: Enzon, Inc.
    Inventors: Robert G. L. Shorr, Mike A. Clark
  • Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
    Patent number: 5367063
    Abstract: The invention provides methods for detecting elevated levels of phospholipase A.sub.2 activating protein in persons suspected of having rheumatiod arthritis to thereby indicate the presence of rheumatoid arthritis in the person comprising the steps of providing a sample of body fluid or tissue from said person; contacting the sample with an antibody specific for phospholipase A.sub.2 activating protein such that the antibody binds with phospholipase A.sub.2 activating protein in the sample; detecting the antibody thereby indicating the presence of phospholipase A.sub.2 activating protein, whereby elevated levels of phospholipase A.sub.2 activating protein in the sample as compared with levels found in persons not having rheumatoid arthritis indicates the presence of rheumatoid arthritis in the person. Kits and reagents for detecting rheumatoid arthritis are also provided.
    Type: Grant
    Filed: November 4, 1993
    Date of Patent: November 22, 1994
    Inventors: John S. Bomalaski, Mike A. Clark, Robert Shorr